Research programme: 212-Pb immunoconjugates - AREVA Med/Roche

Drug Profile

Research programme: 212-Pb immunoconjugates - AREVA Med/Roche

Alternative Names: 212-Pb radioimmunotherapy - AREVA Med/Roche; Alpha radioimmunotherapies - AREVA Med/Roche; Lead-212 radioimmunotherapy - AREVA Med/Roche

Latest Information Update: 11 Sep 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AREVA Med; Roche
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 Jul 2012 Early research in Cancer in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top